JPH05194585A - Compound uca1064-b - Google Patents

Compound uca1064-b

Info

Publication number
JPH05194585A
JPH05194585A JP5158092A JP5158092A JPH05194585A JP H05194585 A JPH05194585 A JP H05194585A JP 5158092 A JP5158092 A JP 5158092A JP 5158092 A JP5158092 A JP 5158092A JP H05194585 A JPH05194585 A JP H05194585A
Authority
JP
Japan
Prior art keywords
uca1064
culture
formula
mass spectrometry
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP5158092A
Other languages
Japanese (ja)
Inventor
Tatsuya Tamaoki
達也 玉沖
Isami Takahashi
勇美 高橋
Katsuhiko Ando
勝彦 安藤
Mayumi Koda
真由美 好田
Toshiaki Iwasaki
敏明 岩崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to JP5158092A priority Critical patent/JPH05194585A/en
Publication of JPH05194585A publication Critical patent/JPH05194585A/en
Withdrawn legal-status Critical Current

Links

Abstract

PURPOSE:To obtain the subject compound having excellent antimicrobial, antifungal and antitumor actions. CONSTITUTION:The objective compound expressed by the formula. As physico- chemical properties of the compound expressed by the formula. Properties; white powder. Molecular formula; C28H47NO. Molecular weight; 413. Mass spectrometry; secondary ion mass spectrometry (SIMS); 414(M+1)<+> and electron ionization mass spectrometry (EIMS); 413(M+1)<+>. Specific rotatory power; [alpha]D<24>=-28.5 deg. (C=0.5, methanol). Ultraviolet absorption spectrum (methanol solution) lambdamax-nm (epsilon); 279 (8700) (under acidic conditions) and 241 (7500) (under basic conditions). Color reaction; exhibiting positiveness to vanillin sulfuric acid, iodine, etc. The compound expressed by the formula is obtained by culturing Wallemia.sebi KAC-1341 strain (FERM BP-3270), preferably at 25-32 deg.C and pH 6-8 for 1-7 days according to a liquid culture (preferably submerged spinner culture) method, etc.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は化合物UCA1064-B に関す
る。UCA1064-B は抗菌、抗真菌作用および抗腫瘍作用を
有し、抗菌、抗真菌剤および抗腫瘍剤として有用であ
る。
This invention relates to the compound UCA1064-B. UCA1064-B has antibacterial, antifungal and antitumor effects and is useful as an antibacterial, antifungal and antitumor agent.

【0002】[0002]

【従来の技術】本発明化合物に構造的に類似の化合物と
しては、式(II)
2. Description of the Related Art A compound structurally similar to the compound of the present invention is represented by the formula (II)

【0003】[0003]

【化2】 [Chemical 2]

【0004】で表される化合物A25822B が知られている
〔ジャーナル オブ アンチビオティクス(THE JOURNAL
OF ANTIBIOTICS), 27(12), 992(1974) 〕が、化合物A2
5822Bが抗腫瘍作用を有するという報告はない。
[0004] The compound A25822B represented by [Journal of Antibiotics (THE JOURNAL
OF ANTIBIOTICS), 27 (12), 992 (1974)] is compound A2
There is no report that 5822B has an antitumor effect.

【0005】[0005]

【発明が解決しようとする課題】本発明の目的は、優れ
た抗菌、抗真菌作用および抗腫瘍作用を有する化合物を
提供することにある。
The object of the present invention is to provide a compound having excellent antibacterial, antifungal and antitumor effects.

【0006】[0006]

【課題を解決するための手段】本発明者らは、市販のホ
シイモから分離した微生物を培地に培養して得られる培
養物中に抗菌、抗真菌および抗腫瘍作用を有する物質が
生産されることを見出した。この物質を単離、精製し、
その理化学的性質を調べた結果、新規物質であることが
判明し、UCA1064-B と命名した。
[Means for Solving the Problems] The inventors of the present invention have found that substances having antibacterial, antifungal and antitumor effects are produced in a culture obtained by culturing microorganisms isolated from commercial potatoes in a medium. Found. Isolate and purify this material,
As a result of examining its physicochemical properties, it was found to be a novel substance, and it was named UCA1064-B.

【0007】本発明によれば、式(I)According to the invention, the formula (I)

【0008】[0008]

【化3】 [Chemical 3]

【0009】で表される化合物UCA1064-B を提供するこ
とができる。該化合物はヴァレミア属に属する微生物を
培養することにより得ることができる。以下に本発明を
詳細に説明する。UCA1064-B の理化学的性質を以下に示
す。
A compound UCA1064-B represented by can be provided. The compound can be obtained by culturing a microorganism belonging to the genus Valemia. The present invention will be described in detail below. The physicochemical properties of UCA1064-B are shown below.

【0010】(i) 性 状 : 白色粉末 (ii) 分子式 : C28H47NO (iii) 分子量 : 413 (iv) 質量分析 : SIMS 414(M+1) + , EIMS 413(M+1)
+ (v) 比旋光度 :〔α〕D 24= -28.5°(c=0.5, メタ
ノール) (vi) 紫外部吸収スペクトル(メタノール溶液) λmax nm (ε): 279 (8,700)(酸性条件下) 241 (7,500)(塩基性条件下) (vii) 赤外部吸収スペクトル (クロロホルム溶液) ν (cm-1) : 3400, 2950, 1690, 1610, 1450, 1370,
1070 (viii) 1H-NMR(500MHz, CDCl3 ) (δ)3.97(1H), 3.64(1H), 3.50(1H), 1.03(3H,s), 0.95
(3H,s), 0.93(3H,d,J=6.9Hz), 0.86(3H,d,J=6.8Hz), 0.
79(3H,d,J=6.8Hz), 0.77(3H,d,J=6.8Hz). (ix) 13C-NMR(100MHz, CDCl3 ) (δ) 172.7(s), 147.3(s), 127.5(s), 70.9(d), 51.2
(t), 48.3(d), 40.7(d),39.0(d), 38.2(t), 37.7(s), 3
7.2(s), 34.9(t), 33.4(t), 33.4(t), 31.7(d),31.6
(d), 31.5(t), 30.5(t), 27.2(t), 25.5(t), 21.7(q),
20.7(t), 20.4(q),19.2(t), 18.5(q), 17.8(q), 16.8
(q), 15.5(q). (x) 呈色反応 : バニリン硫酸、ヨウ素に陽性。
(I) Properties: White powder (ii) Molecular formula: C 28 H 47 NO (iii) Molecular weight: 413 (iv) Mass spectrometry: SIMS 414 (M + 1) + , EIMS 413 (M + 1)
+ (V) Specific rotation: [α] D 24 = -28.5 ° (c = 0.5, methanol) (vi) UV absorption spectrum (methanol solution) λ max nm (ε): 279 (8,700) (under acidic condition) 241 (7,500) (under basic conditions) (vii) Red external absorption spectrum (chloroform solution) ν (cm -1 ): 3400, 2950, 1690, 1610, 1450, 1370,
1070 (viii) 1 H-NMR (500MHz, CDCl 3 ) (δ) 3.97 (1H), 3.64 (1H), 3.50 (1H), 1.03 (3H, s), 0.95
(3H, s), 0.93 (3H, d, J = 6.9Hz), 0.86 (3H, d, J = 6.8Hz), 0.
79 (3H, d, J = 6.8Hz), 0.77 (3H, d, J = 6.8Hz). (Ix) 13 C-NMR (100MHz, CDCl 3 ) (δ) 172.7 (s), 147.3 (s), 127.5 (s), 70.9 (d), 51.2
(t), 48.3 (d), 40.7 (d), 39.0 (d), 38.2 (t), 37.7 (s), 3
7.2 (s), 34.9 (t), 33.4 (t), 33.4 (t), 31.7 (d), 31.6
(d), 31.5 (t), 30.5 (t), 27.2 (t), 25.5 (t), 21.7 (q),
20.7 (t), 20.4 (q), 19.2 (t), 18.5 (q), 17.8 (q), 16.8
(q), 15.5 (q). (x) Color reaction: positive for vanillin sulfate and iodine.

【0011】(xi) 溶解性 : アルコール、アセト
ン、酢酸エチル、クロロホルムに可溶、水、ヘキサンに
不溶。 (xii)シリカゲル薄層クロマトグラフィー(TLC) : 薄層 ; Art. 5715 (メルク社製) 展開溶媒 ; クロロホルム:メタノール=85 : 15 Rf値 ; 0.35 (xiii ) 高速液体クロマトグラフィー(HPLC) : カラム ; wako sil 5C18 (和光純薬社製) 流速 ; 1ml/min 移動相 ; 80% メタノール〔10mM クエン酸−リン酸
緩衝液(pH 4.0)〕 保持時間 ; 13.5min
(Xi) Solubility: Soluble in alcohol, acetone, ethyl acetate and chloroform, insoluble in water and hexane. (Xii) Silica gel thin layer chromatography (TLC): thin layer; Art. 5715 (manufactured by Merck & Co.) developing solvent; chloroform: methanol = 85: 15 Rf value; 0.35 (xiii) high performance liquid chromatography (HPLC): column; wako sil 5C18 (Wako Pure Chemical Industries, Ltd.) Flow rate: 1 ml / min Mobile phase: 80% Methanol [10 mM citric acid-phosphate buffer (pH 4.0)] Retention time: 13.5 min

【0012】次にUCA1064-B の生物活性について説明す
る。 (A) 抗菌、抗真菌作用 バクトトリプトン (Difco 社製)3g,肉エキス3g, 酵母
エキス1g,グルコース1g, 寒天16g を1リットルの水に
溶解して作製した培地(pH7) を用いて寒天希釈法により
各種細菌および真菌に対する最小生育阻止濃度 (MIC)を
測定した。その結果を第1表に示す。
Next, the biological activity of UCA1064-B will be described. (A) Antibacterial and antifungal action Agar using a medium (pH 7) prepared by dissolving 3 g of bactotryptone (manufactured by Difco), 3 g of meat extract, 1 g of yeast extract, 1 g of glucose and 16 g of agar in 1 liter of water. The minimum inhibitory concentration (MIC) against various bacteria and fungi was measured by the dilution method. The results are shown in Table 1.

【0013】[0013]

【表1】 [Table 1]

【0014】(B) 発ガン遺伝子H-ras で形質転換したBA
LB 3T3細胞(以下、BALB 3T3/H-ras細胞と略記する)に
対する生育阻害 DME 培地(ニッスイ製薬社製)および10%牛胎児血清か
ら成る培地(以下、培地A とする)にBALB 3T3/H-ras細
胞を懸濁したBALB 3T3/H-ras細胞懸濁液(3 ×104 個/m
l)を0.1 mlずつ96穴マイクロタイタープレートの各穴に
分注した。該プレートを炭酸ガスインキュベーター内で
37℃, 20時間培養後、培地A によりUCA1064-B を適宣段
階的に希釈した検体 0.1 ml ずつを各穴に加えた。その
後、炭酸ガスインキュベーター内で37℃、72時間培養し
た。培養上清を除去後、残渣を生理食塩水で1回洗浄
後、0.1 mlのメタノールで10分間処理し細胞を固定した
後、0.1 mlのギムザ染色液〔ギムザ染色液 Merck Art92
04(メルク社製):生理食塩水=1:10〕で5分間細胞を染
色した。染色液を除去後、残渣を0.2 mlの水で1回洗浄
し、ついで、0.1 規定塩酸 0.2 ml で色素を抽出後、マ
イクロプレートリーダーにより620 nmの吸光度を測定し
た。無処理細胞と既知濃度の検体で処理した細胞の吸光
度を比較することにより細胞の増殖を50% 阻害する検体
濃度 (IC50) を算出した。その結果を第2表に示す。
(B) BA transformed with the oncogene H-ras
Growth inhibition against LB 3T3 cells (hereinafter abbreviated as BALB 3T3 / H-ras cells) BALB 3T3 / H in DME medium (manufactured by Nissui Pharmaceutical Co., Ltd.) and 10% fetal calf serum (hereinafter referred to as medium A) -BALB 3T3 / H-ras cell suspension containing ras cells (3 × 10 4 cells / m
l) was dispensed in 0.1 ml portions into each well of a 96-well microtiter plate. Place the plate in a carbon dioxide incubator
After culturing at 37 ° C. for 20 hours, 0.1 ml of each sample of UCA1064-B appropriately diluted stepwise with medium A was added to each well. Then, the cells were cultured in a carbon dioxide gas incubator at 37 ° C for 72 hours. After removing the culture supernatant, the residue was washed once with physiological saline, treated with 0.1 ml of methanol for 10 minutes to fix the cells, and then 0.1 ml of Giemsa stain [Giemsa stain Merck Art92
04 (manufactured by Merck): physiological saline = 1:10], and the cells were stained for 5 minutes. After removing the staining solution, the residue was washed once with 0.2 ml of water, and then the dye was extracted with 0.2 ml of 0.1 N hydrochloric acid, and then the absorbance at 620 nm was measured by a microplate reader. The sample concentration (IC 50 ) at which cell growth was inhibited by 50% was calculated by comparing the absorbances of untreated cells and cells treated with a sample of known concentration. The results are shown in Table 2.

【0015】[0015]

【表2】 [Table 2]

【0016】(C) マウス乳癌SC-4に対する抗腫瘍作用 BALB/c nu/nuヌードマウス(5週令、雄)に、約2mm角
(8mm3)の大きさに切り出したSC-4腫瘍を、トロアカール
を用いて腹側部に皮下移植した。腫瘍の体積が100-300m
m3に達したら、UCA1064-B を1日1回 15mg/kgで4日
間、腫瘍近傍に皮下投与した。UCA1064-B はTween80 お
よび0.3% CMC(カルボキシメチルセルロース)液で懸濁
〔UCA1064-B 10mg当たり、Tween80 を20μl加えて混ぜ
合わせ、その後0.3% CMC液で懸濁液とする〕し、投与し
た。
(C) Antitumor activity against mouse breast cancer SC-4 BALB / c nu / nu nude mice (5 weeks old, male) were about 2 mm square.
SC-4 tumors cut to a size of (8 mm 3 ) were subcutaneously transplanted on the ventral side using a trocar. Tumor volume is 100-300 m
Upon reaching m 3, 4 days UCA1064-B once 15 mg / kg 1 day, it was administered subcutaneously to the tumor vicinity. UCA1064-B was suspended in Tween80 and a 0.3% CMC (carboxymethylcellulose) solution [20 μl of Tween80 was added to 10 mg of UCA1064-B and mixed, and then a suspension was prepared in a 0.3% CMC solution] and administered.

【0017】比較例として、コーチゾンを1日1回 100
mg/kg で5日間、上記と同様の方法で皮下投与した。抗
腫瘍効果は、薬剤投与開始後5日目に T/C(T:試験群の
腫瘍体積 C:対照群の腫瘍体積)として判定した。結果
を第3表に示す。
As a comparative example, 100 g of cortisone was administered once a day.
Subcutaneous administration was performed in the same manner as above for 5 days at mg / kg. The antitumor effect was determined as T / C (T: tumor volume of test group C: tumor volume of control group) 5 days after the start of drug administration. The results are shown in Table 3.

【0018】[0018]

【表3】 [Table 3]

【0019】上記の結果よりUCA1064-B は、癌細胞の生
育を阻害することが明らかである。次にUCA1064-B の製
造法について説明する。UCA1064-B は、ヴァレミア(Wal
lemia) 属に属し、UCA1064-B を生産する能力を有する
微生物を培地に培養し、培養物中にUCA1064-B を生成蓄
積させ、該培養物からUCA1064-B を採取することによっ
て得ることができる。
From the above results, it is clear that UCA1064-B inhibits the growth of cancer cells. Next, a method for manufacturing UCA1064-B will be described. UCA1064-B is the
It can be obtained by culturing in a medium a microorganism belonging to the genus Lemia) and having the ability to produce UCA1064-B, producing and accumulating UCA1064-B in the culture, and collecting UCA1064-B from the culture. ..

【0020】UCA1064-B 生産菌株としては、ヴァレミア
属に属し、UCA1064-B 生産能を有する菌株であればいず
れの菌株でも用いることができる。またこれらの菌株を
人工的変異方法、例えば紫外線照射、X線照射、変異誘
起剤処理などによって変異させた変異株あるいは自然的
に変異した変異株でもUCA1064-B を生産するものであれ
ば本発明に用いることができる。代表的菌株としては、
ヴァレミア セビ (Wallemia sebi)KAC-1341株(以下、
KAC-1341株と略記する)があげられる。
As the UCA1064-B producing strain, any strain can be used as long as it is a strain belonging to the genus Valemia and capable of producing UCA1064-B. The present invention is also applicable to any mutant strains obtained by artificially mutating these strains by, for example, ultraviolet irradiation, X-ray irradiation, treatment with a mutagen, or naturally mutated strains as long as they can produce UCA1064-B. Can be used for. As a typical strain,
Wallemia sebi KAC-1341 strain (hereinafter,
Abbreviated as KAC-1341 strain).

【0021】以下に、KAC-1341株の菌学的性質について
述べる。 肉眼的観察 麦芽エキス寒天培地を用いて、25℃で培養したとき、
集落の直径は培養14日目で6〜9mmに達する。集落
表面はくすんだ淡紅色を呈し、裏面は、暗褐色で、その
周囲は褐色がかったクリーム色を呈する。
The mycological properties of the KAC-1341 strain will be described below. Macroscopic observation When cultured at 25 ° C. using malt extract agar medium,
The diameter of the colony reaches 6-9 mm on day 14 of culture. The surface of the village is dull pink, the back is dark brown, and the surrounding area is brownish cream.

【0022】バレイショ・ブドウ糖寒天培地を用いて、
25℃で培養したとき、集落の直径は培養14日目で6
〜11mmに達する。集落表面は淡褐色がかった狐色を
呈し、裏面は灰黒色で、その周囲はクリーム色を呈す
る。40%ショ糖添加麦芽エキス・酵母エキス寒天培地
[ハロルドのM40Y(Harrold's M40Y)]を用いて、2
5℃で培養したとき、集落の直径は培養14日目で11
〜15mmに達する。集落表面は灰色がかった淡紅色を
呈し、裏面は茶褐色で、その周囲は淡褐色を呈する。本
菌株の至適生育温度は12〜30℃であり、25℃前後
で最も良好に生育する。生育し得るpHは4〜7で至適
生育pHは、5.5〜6.5である。
Using potato-glucose agar medium,
When cultured at 25 ° C, the diameter of the colony was 6 after 14 days of culture.
Reach ~ 11 mm. The surface of the village is light brownish fox, the back is grayish black, and the surrounding area is creamy. Using malt extract / yeast extract agar medium with 40% sucrose [Harrold's M40Y], 2
When cultivated at 5 ° C, the diameter of the colony was 11 after 14 days of culture.
Reach ~ 15 mm. The surface of the village is grayish light pink, the back surface is dark brown, and the surrounding area is light brown. The optimum growth temperature of this strain is 12 to 30 ° C, and it grows best at around 25 ° C. The pH that can grow is 4 to 7, and the optimum growth pH is 5.5 to 6.5.

【0023】 40%ショ糖添加麦芽エキス・酵母エ
キス寒天培地上で培養したときの本菌株の光学顕微鏡的
観察 菌糸は隔壁を有し、無色、平滑でよく分岐する。分生子
柄は菌糸から単生し、先端に円筒形あるいはフラスコ形
のフィアライド様の分生子形成細胞を形成する。また、
分生子形成細胞が先端伸長し、それを繰り返すことによ
り分生子柄が長くなる場合もある。分生子形成細胞先端
から、円筒形の分生子原細胞が伸長する。分生子原細胞
は、長さ約30μm 、幅2〜2.5μm で、基部はやや太
くなり幅2.5〜3.0μm を呈する。分生子原細胞の先端
から基部に向かい1.5〜2.5μmの幅で隔壁が形成され
てゆき、やがてその隔壁部で各細胞は分離し、各々が単
細胞性の分節型分生子となる。分節型分生子は、はじめ
無色、平滑で四角形を呈するが、成熟するに従い淡褐
色、表面はわずかな刺状あるいは疣状を呈するようにな
り、球形または亜球形となる。成熟した分生子は、直径
2.5〜3.5μm で、壁はやや厚い。本菌株は、以上示し
たアナモルフのみ観察され、テレオモルフは観察されな
い。
Optical Microscopic Observation of This Strain When Cultivated on 40% Sucrose-Added Malt Extract / Yeast Extract Agar Medium Mycelium has a septum and is colorless, smooth and well branched. The conidia stalk singulates from hyphae and forms a cylindrical or flask-shaped filaride-like conidial cell at the tip. Also,
In some cases, the conidia-forming cells are elongated at the tip and the conidia stalk becomes longer by repeating the elongation. Cylindrical conidia progenitor cells extend from the tip of conidia forming cells. Conidia progenitor cells have a length of about 30 μm and a width of 2 to 2.5 μm, and have a slightly thicker base and a width of 2.5 to 3.0 μm. A septum having a width of 1.5 to 2.5 μm is formed from the tip to the base of the conidia progenitor cell, and each cell is separated at the septum, and each becomes a unicellular segmental conidia. Segmental conidia are initially colorless, smooth, and square-shaped, but as they mature, they become pale brown, and the surface becomes slightly spiny or wart-like, spherical or subspherical. Mature conidia have diameter
The thickness is 2.5 to 3.5 μm, and the wall is slightly thick. In this strain, only the anamorphs shown above are observed, and teleomorphs are not observed.

【0024】以上の菌学的性質より、本菌の分類学上の
位置をエリス(M. B. Ellis)著の「デマチアシアス・ハ
イフォミセテス(DEMATIACEOUS HYPHOMYCETES)37-38(197
1)」に従って検索した結果、本菌株は、ヴァレミア・セ
ビ (フリース) フォンアクス(Wallemia sebi (Fri
es) von Arx )と同定された。本発明者らは、本菌株を
ヴァレミア・セビ KAC−1341と命名し、ブダペ
スト条約に基づき、平成3年2月12日付で微工研条寄
第3270号(FERM BP-3270)として工業技術院微生物工業技
術研究所に寄託した。
From the above mycological properties, the taxonomic position of this bacterium was determined by MB Ellis in "DEMATIACEOUS HYPHOMYCETES" 37-38 (197).
1) ”, the strain was found to be Wallemia sebi (Fri
es) von Arx). The present inventors named this strain Valemia sevi KAC-1341, and based on the Budapest Treaty, it was designated as Micro Engineering Research Article No. 3270 (FERM BP-3270) on February 12, 1991. Deposited at Institute of Microbial Technology.

【0025】本発明のUCA1064-B 生産株の培養において
は通常の真菌の培養法が一般に用いられる。培地として
は、菌の資化し得る炭素源、窒素源、無機物などを程よ
く含有する培地であれば合成培地、天然培地いずれでも
用いられる。炭素源としては、グルコース、澱粉、デキ
ストリン、マンノース、シュークロース、ラクトース、
キシロース、アラビノース、マンニトール、糖蜜などが
単独または組み合わせて用いられる。さらに、菌の資化
能によっては炭化水素、アルコール類、有機酸なども用
いられる。窒素源としては塩化アンモニウム、硫酸アン
モニウム、硝酸アンモニウム、硝酸ナトリウム、尿素、
ペプトン、肉エキス、酵母エキス、乾燥酵母、コーンス
チープリカー、 大豆粉、カザミノ酸などが単独または組
み合わせて用いられる。そのほか、必要に応じて食塩、
塩化カリウム、硫酸マグネシウム、炭酸カルシウム、リ
ン酸二水素カリウム、リン酸水素二カリウム、硫酸第一
鉄、塩化カルシウム、硫酸マンガン、硫酸亜鉛、硫酸銅
などの無機塩類を加えることができる。さらに使用する
菌の生育やUCA1064-B の生産を促進する物質、例えばビ
タミンB1、ビオチンなどを添加することができる。
In culturing the UCA1064-B producing strain of the present invention, a general fungal culture method is generally used. As the medium, either a synthetic medium or a natural medium can be used as long as it contains a carbon source, a nitrogen source, an inorganic substance and the like that can be assimilated by the bacterium. Carbon sources include glucose, starch, dextrin, mannose, sucrose, lactose,
Xylose, arabinose, mannitol, molasses, etc. are used alone or in combination. Further, depending on the assimilation ability of the bacterium, hydrocarbons, alcohols, organic acids, etc. are also used. As a nitrogen source, ammonium chloride, ammonium sulfate, ammonium nitrate, sodium nitrate, urea,
Peptone, meat extract, yeast extract, dry yeast, corn steep liquor, soybean powder, casamino acid, etc. may be used alone or in combination. In addition, salt if necessary,
Inorganic salts such as potassium chloride, magnesium sulfate, calcium carbonate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, ferrous sulfate, calcium chloride, manganese sulfate, zinc sulfate and copper sulfate can be added. Further, substances that promote the growth of the bacterium used and the production of UCA1064-B, such as vitamin B 1 and biotin, can be added.

【0026】培養は、液体培養法、固体培養法でもよい
が、通常は液体培養法、特に深部攪拌培養法により、温
度16-37 ℃、好ましくは 25-32℃で、pH4-10、好ましく
は pH6-8で行われる。通常1-7 日の培養によって目的物
質UCA1064-B が培養液中および菌体中に生成蓄積され
る。培養中、培地のpH調整にはアンモニア水や炭酸アン
モニウム溶液などが用いられる。培養物中の生成量が最
大に達したときに培養を停止し、培養物中よりUCA1064-
B を単離精製する。
The culture may be a liquid culture method or a solid culture method, but is usually a liquid culture method, particularly a deep agitation culture method at a temperature of 16-37 ° C., preferably 25-32 ° C., and a pH of 4-10, preferably. It is carried out at pH 6-8. Normally, the target substance UCA1064-B is produced and accumulated in the culture solution and in the cells by culturing for 1-7 days. During the culturing, aqueous ammonia, ammonium carbonate solution, etc. are used to adjust the pH of the medium. When the amount of production in the culture reached the maximum, the culture was stopped and the UCA1064-
Isolate and purify B.

【0027】培養物からUCA1064-B の単離精製は、微生
物代謝産物をその培養物から単離精製するために常用さ
れる方法に従って行われる。例えば培養物を濾過また
は、遠心分離により培養濾液と菌体とに分け、菌体をク
ロロホルム、アセトンなどで抽出する。ついで、抽出液
と培養濾液とを合わせて、ポリスチレン系吸着樹脂、例
えばダイヤイオンHP20(三菱化成社製)などに通塔して
活性成分を吸着させ、酢酸エチル、アセトン、メタノー
ルなどで溶出する。溶出液を濃縮し、シリカゲルによる
カラムクロマトグラフィー、高速液体クロマトグラフィ
ーなどにより、UCA1064-B の白色粉末を得る。なお、培
養、精製工程中のUCA1064-B の動向は、高速液体クロマ
トグラフィーにより追跡することができる。
The isolation and purification of UCA1064-B from the culture is carried out according to the conventional method for isolating and purifying microbial metabolites from the culture. For example, the culture is separated by filtration or centrifugation into a culture filtrate and cells, and the cells are extracted with chloroform, acetone or the like. Then, the extract and the culture filtrate are combined and passed through a polystyrene-based adsorption resin such as Diaion HP20 (manufactured by Mitsubishi Kasei Co.) to adsorb the active ingredient, and eluted with ethyl acetate, acetone, methanol or the like. The eluate is concentrated and the white powder of UCA1064-B is obtained by column chromatography on silica gel, high performance liquid chromatography and the like. The trend of UCA1064-B during the culture and purification steps can be followed by high performance liquid chromatography.

【0028】以下に本発明の実施例を示す。Examples of the present invention will be shown below.

【0029】[0029]

【実施例】【Example】

実施例1 種菌としてヴァレミア・セビKAC-1341株(FERM BP-3270)
を用いた。該菌株を2リットル容量の三角フラスコ中の
V8野菜ジュース(キャンベル社製)200g/lおよびシュー
クロース 30g/lの組成からなる種培地(殺菌前pH 6.0)
300 mlに植菌し、25℃で96時間振とう(200 rpm) 培養し
た。
Example 1 Valemia sevi strain KAC-1341 (FERM BP-3270) as an inoculum
Was used. The strain was placed in a 2 liter Erlenmeyer flask.
Seed medium consisting of V8 vegetable juice (Campbell) 200 g / l and sucrose 30 g / l (pH 6.0 before sterilization)
The cells were inoculated into 300 ml and cultured at 25 ° C for 96 hours with shaking (200 rpm).

【0030】このようにして得られた種培養液を30リッ
トル容量の培養槽中の上記組成と同一の培地15リットル
に5%(容量)の割合で移し、25℃で96時間攪拌方式(回
転数200 rpm 、通気量15 l/min)により培養を行った。
このようにして得られた培養液を 200リットル容量の培
養槽中の上記組成と同一の培地100 リットルに10% (容
量)の割合で移し、25℃で96時間攪拌方式により培養を
行った。このようにして得られた培養液を 2000 リット
ル容量の培養槽中の下記組成の発酵培地1000リットルに
10% (容量)の割合で移し、培地のpHはとくに制御しな
いで、25℃で96時間攪拌方式により培養を行った。 発酵培地組成:シュークロース 60 g/l, 酵母エキス 30
g/l, KH2PO4 0.5 g/l,MgSO4・7H2O 0.5 g/l (殺菌前p
H 6.0)
The seed culture thus obtained was transferred at a rate of 5% (volume) to 15 liters of the same medium as the above composition in a culture vessel having a volume of 30 liters and stirred at 25 ° C. for 96 hours (rotation method). The culture was performed at several 200 rpm and an aeration rate of 15 l / min).
The thus obtained culture solution was transferred to 100 liters of the same medium as the above composition in a 200 liter-volume culture tank at a rate of 10% (volume), and cultured at 25 ° C. for 96 hours by a stirring system. The culture broth thus obtained was added to 1000 liters of fermentation medium of the following composition in a 2000-liter capacity culture tank.
The medium was transferred at a rate of 10% (volume), and the pH of the medium was not particularly controlled, and the cells were cultured at 25 ° C. for 96 hours by a stirring method. Fermentation medium composition: Sucrose 60 g / l, yeast extract 30
g / l, KH 2 PO 4 0.5 g / l, MgSO 4 · 7H 2 O 0.5 g / l ( before sterilization p
H 6.0)

【0031】培養液にn-プロパノール500 リットルを添
加し攪拌した後、培養物から菌体および沈澱物を濾別
し、濾液1500リットルを得た。濾液をpH8.0 に調整した
後、ポリスチレン系吸着樹脂ダイヤイオンHP20(50 リッ
トル)のカラムに通塔して活性物質を吸着させた。脱イ
オン水および30% メタノールで不純物を溶出後100%メタ
ノールで活性物質を溶出した。活性画分を濃縮後水を加
えpH10.0に調整し、酢酸エチルで抽出した。酢酸エチル
層を濃縮すると茶色オイル状物質100gが得られた。茶色
オイル状物質をシリカゲル(Art.7734;メルク社製)のカ
ラムにかけクロロホルム、ついでクロロホルムとメタノ
ール(9:1)との混合溶媒を用い、不純物を溶出させた
後、クロロホルムとメタノール(8:2)との混合溶媒を用
い活性物質を溶出した。活性物質を含む画分を濃縮し、
得られた物質をシリカゲル(Art. 9390Lichroprep Si6
0;メルク社製) を充填したカラムにかけ、クロロホル
ム、ついでクロロホルムとメタノール(8:2)との混合溶
媒で溶出した。活性画分を濃縮し、次に逆相系シリカゲ
ル(YMC ODS SH-363-5,ワイエムシー社製) を用い、80%
メタノール(クエン酸 -リン酸緩衝液pH4.0)を溶離液
として高速液体クロマトグラフィーを行いUCA1064-B を
分取し、UCA1064-B の白色粉末100 mgを得た。
After adding 500 liters of n-propanol to the culture medium and stirring, cells and precipitates were separated from the culture by filtration to obtain 1500 liters of filtrate. The pH of the filtrate was adjusted to 8.0, and the column was passed through a column of polystyrene-based adsorption resin Diaion HP20 (50 liters) to adsorb the active substance. Impurities were eluted with deionized water and 30% methanol and then the active substance was eluted with 100% methanol. The active fraction was concentrated, water was added to adjust the pH to 10.0, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was concentrated to obtain 100 g of a brown oily substance. The brown oily substance was applied to a column of silica gel (Art.7734; manufactured by Merck) and chloroform was used to elute impurities using a mixed solvent of chloroform and methanol (9: 1), followed by chloroform and methanol (8: 2). The active substance was eluted using a mixed solvent with (1). Concentrate the fractions containing the active substance,
The obtained substance was converted to silica gel (Art. 9390Lichroprep Si6
0; manufactured by Merck & Co., Inc.) and applied to a column filled with chloroform, followed by elution with chloroform and then with a mixed solvent of chloroform and methanol (8: 2). Concentrate the active fraction, then use reverse-phase silica gel (YMC ODS SH-363-5, YMC) to obtain 80%
High performance liquid chromatography was performed using methanol (citric acid-phosphate buffer pH 4.0) as an eluent to separate UCA1064-B to obtain 100 mg of UCA1064-B as a white powder.

【0032】実施例2 実施例1に用いた発酵培地組成を次のものに代えて行う
以外は、実施例1と同様に行い、UCA1064-B の白色粉末
60mgを得た。 発酵培地組成:グルコース 60 g/l, 酵母エキス 30 g/
l, KH2PO4 0.5 g/l, MgSO 4・7H2O 0.5 g/l (殺菌前pH
6.0)
Example 2 The fermentation medium composition used in Example 1 is replaced with the following.
Except for this, the same procedure as in Example 1 is carried out to obtain UCA1064-B white powder.
60 mg was obtained. Fermentation medium composition: glucose 60 g / l, yeast extract 30 g /
l, KH2POFour0.5 g / l, MgSO Four・ 7H2O 0.5 g / l (pH before sterilization
6.0)

【0033】[0033]

【発明の効果】本発明により抗菌、抗真菌および抗腫瘍
作用を有する新規化合物UCA1064-B が提供される。
INDUSTRIAL APPLICABILITY The present invention provides a novel compound UCA1064-B having antibacterial, antifungal and antitumor activity.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 C12R 1:645) 7804−4B ─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 5 Identification code Office reference number FI technical display location C12R 1: 645) 7804-4B

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 式(I) 【化1】 で表される化合物UCA1064-B。1. Formula (I): The compound UCA1064-B represented by.
JP5158092A 1991-03-13 1992-03-10 Compound uca1064-b Withdrawn JPH05194585A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5158092A JPH05194585A (en) 1991-03-13 1992-03-10 Compound uca1064-b

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3-48206 1991-03-13
JP4820691 1991-03-13
JP5158092A JPH05194585A (en) 1991-03-13 1992-03-10 Compound uca1064-b

Publications (1)

Publication Number Publication Date
JPH05194585A true JPH05194585A (en) 1993-08-03

Family

ID=26388440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5158092A Withdrawn JPH05194585A (en) 1991-03-13 1992-03-10 Compound uca1064-b

Country Status (1)

Country Link
JP (1) JPH05194585A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015535223A (en) * 2012-10-22 2015-12-10 オロン エス.ピー.エー. Purification method of abiraterone acetate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015535223A (en) * 2012-10-22 2015-12-10 オロン エス.ピー.エー. Purification method of abiraterone acetate

Similar Documents

Publication Publication Date Title
YOSHIDA et al. A novel antifungal antibiotic, fr-900848 i. production, isolation, physico-chemical and biological properties
JPH05194585A (en) Compound uca1064-b
JP2768829B2 (en) Antibiotics
US5236929A (en) Compound uca1064-b
JP2695225B2 (en) New substance UCT-1003
HU202284B (en) Process for producing new azoxy derivatives and pharmaceutical compositions comprising same as active ingredient
US6521600B1 (en) Compound, WF002, production thereof and use thereof
US5036008A (en) Antitumor antibiotic BU-3285T
EP0284358B1 (en) Novel anti-tumor compounds, method for the preparation thereof, and pharmaceutical preparations containing them
JPH01112988A (en) Dc-107 and production thereof
CA1338169C (en) Compounds wf 2015 a and b, production thereof and use thereof
JPH05155877A (en) Novel substances: urauchimycin a and urauchimycin b and production thereof
US5441987A (en) Antifungal agent
CA2020878C (en) Antitumor antibiotic bu-3285t
JP2766351B2 (en) New substance DC114-C
JPH02218686A (en) Dc1149b, dc1149r and production thereof
JPH05255305A (en) New bioactive substance k-18, its use and its production
US5089522A (en) Antitumor antibiotic BU-3285T
CA2008628C (en) Substance uct-1003 and process for producing the same
JPH1112296A (en) Antifungal compound afa0424
WO1999061645A1 (en) Novel compound, wf00144
JPS6330492A (en) Novel antibiotic al-r2397 substance and production thereof
WO2001029182A1 (en) Novel compound, wf217
WO1995018142A1 (en) Wf15604 substances
JPH07107989A (en) New antibiotic mk8062 substance and its production

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 19990518